- Global Pharma News & Resources

North America Genotyping Market Report 2022: Use of Genotyping in Drug Development for Genetic and Rare Diseases Drives Growth -

DUBLIN--(BUSINESS WIRE)--The "North America Genotyping Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Product and Services, Technology, Application, and End User" report has been added to's offering.

The genotyping market in North America is expected to grow from US$ 11,734.10 million in 2022 to US$ 37,599.28 million by 2028. It is estimated to grow at a CAGR of 21.4% from 2022 to 2028.

Genotyping compares a DNA sequence to another sample or a reference sequence to discover variations in genetic complement. It detects single-nucleotide polymorphisms (SNPs), which are minor differences in genetic sequence within the population. The human genome has about 660 million SNPs, making them the most prevalent kind of genetic variation. They can explain features such as eye color and hereditary disorders such as cystic fibrosis and sickle cell anemia and serve as indicators for developing complicated diseases, such as cancer, diabetes, and Alzheimer's.

Additionally, by comparing polymorphisms in two distinct populations (one healthy and one diseased), genome-wide association studies (GWAS) can uncover links between SNPs and common illness risk. GWAS can begin to untangle the molecular mechanisms underlying disease states by finding probable causative variables risk stratification.

Single-celled organisms, such as bacteria, even have SNPs. SNP genotyping can discriminate between microorganism isolates and might even be accustomed to characterizing antibiotic resistance strains. SNP-based strain detection has relevance in each clinical and pharmaceutical analysis and has been used to study the spread of infectious diseases in humans. Since these conditions are difficult to identify clinically, genotyping is the backbone of diagnostic testing in the population. This rising adoption of prenatal genetic screening to examine children's chromosomal anomalies could prove to be a significant driving factor.

Over the last decade, next-generation sequencing (NGS) technology has enabled simultaneous testing of multiple disease genes, from targeted gene panels to exome sequencing (ES) and genomic sequencing (GS). GS is quickly becoming a practical first-stage test as costs decrease and performance improves.

More and more studies show that GS can detect an unprecedented range of pathogenic abnormalities in a single laboratory. GS has the potential to provide patients with unbiased, rapid, and accurate molecular diagnostics that transcend diverse clinical indications and complex conditions. Therefore, the use in drug development for genetic and rare diseases across the region will act as one of the key factors driving the growth of the genotyping markets.

North America Genotyping Market Segmentation

The North America genotyping market is segmented by products and services, technology, application, end user, and country.

  • Based on products and services, the market is segmented into instruments, reagents and kits, bioinformatics, and genotyping services. The reagents and kits segment is dominating the market in 2022.
  • Based on technology, the market is segmented into microarrays, capillary electrophoresis, sequencing, matrix-assisted laser desorption/ionization-time of flight (Maldi-ToF) mass spectrometry, polymerase chain reaction (PCR), and others. The PCR segment is dominating the market in 2022.
  • Based on application, the market is segmented into pharmacogenomics, diagnostics and personalized medicine, animal genetics, agricultural biotechnology, and others. The diagnostics and personalized medicine segment is dominating the market in 2022.
  • Based on end user, the market is segmented into pharmaceutical and biopharmaceutical companies, diagnostic and research laboratories, academic institutes, and others. The diagnostics and research laboratories segment is dominating the market in 2022.
  • Based on country, the market is segmented into the US, Canada, and Mexico. Further, the US is dominating the market in 2022.

Market Dynamics

Market Drivers

  • Use of Genotyping in Drug Development for Genetic and Rare Diseases
  • Technological Advancements and Rising R&D Investments in Pharmaceutical and Biotechnology

Market Restraints

  • High Cost of Equipment and Shortage of skilled Professionals required for Genotyping process

Market Opportunities

  • Wide Applications of Genotyping

Future Trends

  • Rising focus on Personalized Medicine

Key Topics Covered:

1. Introduction

2. North America Genotyping Market - Key Takeaways

3. Research Methodology

4. North America Genotyping Market - Market Landscape

5. North America Genotyping Market- Key Market Dynamics

6. Genotyping Market- North America Analysis

7. North America Genotyping Market- by Product and Services

8. North America Genotyping Market- by Technology

9. North America Genotyping Market-by Application

10. North America Genotyping Market- by End User

11. North America Genotyping Market- Country Analysis

12. North America Genotyping Market Industry Landscape

13. Company Profiles

14. Appendix

Companies Mentioned

  • BioTek Instruments, Inc.
  • Eurofins Genomics
  • F. Hoffmann-La Roche Ltd.
  • Illumina, Inc.
  • Integrated DNA Technologies, Inc.
  • Thermo Fisher Scientific Inc
  • TrimGen Corporation

For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Editor Details

  • Company:
    • Businesswire
Last Updated: 09-Nov-2022